On October 17, 2025 ClearNote Health, a company focused on improving early detection for some of the deadliest cancers, reported a lineup of presentations at the European Society for Medical Oncology (ESMO) (Free ESMO Whitepaper) Congress 2025 in Berlin taking place October 17-21, 2025. Meeting attendees can review the following presentations to learn about ClearNote Health’s innovative early cancer detection technology and latest clinical research success.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"ClearNote Health looks forward to meeting with the ESMO (Free ESMO Whitepaper) community and presenting the significant advances we’ve achieved in early cancer detection and therapy monitoring through epigenomics." – Samuel Levy, PhD, Chief Scientific Officer, ClearNote Health
Share
"ClearNote Health looks forward to meeting with the ESMO (Free ESMO Whitepaper) community and presenting the significant advances we’ve achieved in early cancer detection and therapy monitoring through epigenomics," said Samuel Levy, PhD, Chief Scientific Officer at ClearNote Health. "Our highly sensitive, noninvasive Avantect Pancreatic Cancer and Multi-Cancer Tests are designed to detect the biological signals of cancer at its earliest stages, when patients are most likely to benefit from treatment. In addition, our Virtuoso platform empowers clinicians and researchers to quantify therapy response and provide prognostic insights into patient outcomes."
Featured Presentations
Scientific Posters
Validation of an epigenomic-based multicancer detection test
Presenter: Stephen R. Quake, Stanford University
Presentation Number: 1745P
Evaluation of a cell-free DNA-based blood test for early detection of pancreatic cancer in high-risk individuals with family history and genetic predisposition
Presenter: Randall Brand, University of Pittsburgh
Presentation Number: 2245P
SAFE-D trial design: Targeted pancreatic cancer surveillance to evaluate resectability rate and stage shift in patients with new onset diabetes
Presenter: Victoria Goss, Southampton Clinical Trials Unit
Presentation Number: 2255TiP
e-Posters
Epigenomic Multicancer Detection Algorithms Capture Disease Biomarkers through Machine Learning
Presenter: Stephen R. Quake, Stanford University
Presentation Number: 1783eP
Epigenomic cancer detection and the relationship with circulating tumor allele fraction
Presenter: Zaed Hamady, University Hospital Southampton
Presentation Number: 246eP
Epigenomic measurement of tumor fraction contributions to cfDNA in a multicancer test
Presenter: Martin Sjöström, Lund University
Presentation Number: 212eP
Epigenomic liquid biopsy for quantification of platinum and PARP inhibitor response in patients with germ line BRCA-associated PDAC
Presenter: Talia Golan, Sheba Medical Center
Presentation Number: 2270eP
(Press release, ClearNote Health, OCT 17, 2025, View Source [SID1234656759])